US › Healthcare

Scinai Immunotherapeutics Ltd (SCNI)

US · Healthcare · Biotechnology

$0.75-16.63%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$467,898

Revenue YoY

-20.2%

Net profit

$-2.0M

EPS

$-0.74

Net margin

-435.4%

Key statistics

Market cap

$1.2M

P/E

0.0

Forward P/E

0.0

P/B

0.22

Book value

$10.71

EPS (TTM)

$20.00

52-week high

$15.50

52-week low

$0.75

50-day MA

$1.98

200-day MA

$4.89

Beta

2.13

Analyst view

with an average price target of $700.00.

Shareholding

Insiders

14.16%

Institutions

3.33%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	0.27%
Virtu Financial LLC	0.14%
XTX Topco Ltd	0.12%
Rhumbline Advisers	0.10%
StoneX Group Inc	0.10%
HRT FINANCIAL LLC	0.09%
CapTrust Financial Advisors	0.09%
UBS Group AG	0.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Scinai Immunotherapeutics Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.